TABLE 1 Ferroptosis inducers
Endocrinology, 114 (5), 15371545.
REDEFINE 1 (NCT05567796), REDEFINE 2 (NCT05394519), REDEFINE 3 (NCT05669755), REDEFINE 4 (NCT06131437), REDEFINE 11 (NCT07011667), REIMAGINE 2 (NCT06065540)
Additionally, following proper storage protocols preserves the compounds integrity and effectiveness
The peptides development was ultimately discontinued in 2007 after a 24-week Phase III trial failed to demonstrate statistically significant weight loss compared to placebo, though research into its regenerative properties has continued
Collagen formation receives a boost through enhanced fibroblast activity via the FAK-paxillin pathway